A modified laboratory test that measures platelet desialylation (the loss of terminal sialic acid) may help distinguish immune thrombocytopeniaThrombocytopenia A platelet count that is lower than normal. (ITP) from inherited forms of thrombocytopenia, according to a study recently published in Transfusion Medicine. The findings could support efforts to better understand immune-mediated platelet disorders, including conditions like fetal and neonatal alloimmune thrombocytopenia (FNAITFetal and neonatal alloimmune thrombocytopenia A rare condition in which a mother’s immune system attacks fetal platelets, leading to dangerously low platelet levels before and/or after birth.).
Platelet desialylation occurs when platelets lose certain sugar molecules from their surface. Researchers believe this process contributes to platelet destruction in some immune-mediated conditions, but its role has been less clear in inherited platelet disorders.
Learn more about FNAIT testing and diagnosis
In the study, researchers used blood samples from people with ITP, people with inherited thrombocytopenia and healthy volunteers, to assess how well the modified test performed. They also examined whether it produced consistent results and could identify differences between the various groups.
Sign up here to get the latest news, perspectives, and information about FNAIT sent directly to your inbox. Registration is free and only takes a minute.
The results showed that the test reliably detected increased platelet desialylation in some people with ITP. However, this change was generally not seen in people with inherited thrombocytopenias, suggesting that platelets are lost through different biological processes in the two conditions.
The updated version of the test also proved to be reliable and easier to perform than previous versions, while still producing consistent results. According to the researchers, this makes it more practical for use in research and could support future clinical applications.
The authors noted that the test is not intended to replace existing diagnostic methods. Instead, it could become an additional tool to help clinicians determine the underlying cause of thrombocytopenia, particularly in cases where the diagnosis is uncertain.
“By providing insight into platelet clearance pathways that are not readily detected by conventional immunohaematological methods, the PDT complements existing diagnostic approaches and expands the biological understanding of thrombocytopenic disorders,” the researchers concluded. “Its ability to identify desialylation-associated platelet clearance may support a more comprehensive evaluation of patients with immune and non-immune thrombocytopenia and contribute to mechanism-informed clinical decision-making.”
